+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pneumovax"

Pneumococcal Vaccine Global Market Report 2024 - Product Thumbnail Image

Pneumococcal Vaccine Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
From
From
From
From
Disease Analysis: Pneumococcal Vaccines - Product Thumbnail Image

Disease Analysis: Pneumococcal Vaccines

  • Report
  • May 2021
  • 45 Pages
  • Global
Pneumococcal Vaccines Market and Forecast Analysis to 2022 - Product Thumbnail Image

Pneumococcal Vaccines Market and Forecast Analysis to 2022

  • Drug Pipelines
  • December 2018
  • 145 Pages
  • Global
From
Pneumovax 23 - Product Thumbnail Image

Pneumovax 23

  • Report
  • December 2018
  • 14 Pages
  • Global
From
  • 15 Results (Page 1 of 1)
Loading Indicator

Pneumovax is a vaccine used to protect against pneumococcal disease, a type of bacterial infection that can cause pneumonia, meningitis, and other serious illnesses. It is recommended for adults over the age of 65, as well as those with certain medical conditions. The vaccine is administered as a single dose, and is available in both injectable and intranasal forms. The pneumococcal vaccine market is a growing segment of the overall vaccine market, with increasing demand for the vaccine due to its effectiveness in preventing serious illnesses. The market is expected to continue to grow in the coming years, driven by rising awareness of the importance of vaccination and increasing government initiatives to promote immunization. The pneumococcal vaccine market is highly competitive, with several major players. These include Merck & Co., GlaxoSmithKline, Pfizer, Sanofi, and AstraZeneca. Show Less Read more